Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04617002

Expanded Access Status : Available

First Posted : November 5, 2020

Last Update Posted : December 3, 2020

Sponsor:

Information provided by (Responsible Party):

Oncoceutics, Inc.

Tracking Information

First Submitted Date

October 29, 2020

First Posted Date

November 5, 2020

Last Update Posted Date

December 3, 2020

Descriptive Information

Brief Title

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Brief Summary

This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.

Detailed Description

Not Provided

Study Type

Expanded Access

Expanded Access Type

Intermediate-size Population

Intervention

Drug: ONC201

ONC201 is an oral, small molecule selective antagonist of DRD2

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Expanded Access Status

Available

Contacts

Contact: Clinical Operations Oncoceutics

1-844-ONCORXS

info@oncoceutics.com

Listed Location Countries

United States

Removed Location Countries

Administrative Information

NCT Number

NCT04617002

Responsible Party

Oncoceutics, Inc.

Study Sponsor

Oncoceutics, Inc.

Collaborators

Not Provided

Investigators

Not Provided

PRS Account

Oncoceutics, Inc.

Verification Date

December 2020

To Top